Company news

Adicet Bio, Inc. news in 2026

Adicet Bio, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

October 30, 2026

Adicet Bio to Participate in Upcoming Investor Conferences

October 22, 2026

Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis

September 28, 2026

Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis

September 25, 2026

Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update

September 1, 2026

Adicet Bio Announces FDA Clearance of IND Application for ADI-212

August 27, 2026

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 5, 2026

Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference

July 21, 2026

Amendment to Annual Report (Form 10-K/A)

May 20, 2026

Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference

May 14, 2026

Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

May 13, 2026

Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

March 12, 2026

Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

January 30, 2026

Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones

January 7, 2026

Decks in 2026